Received May 8, 2026
Reports are unverified and do not show that a vaccine caused an event. Full disclaimer
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 3 | NT357 | — |
3rd dose administered; This non-serious case was reported by a nurse via call center representative and described the occurrence of extra dose administered in a 73-year-old male patient who received Herpes zoster (Shingrix) (batch number NT357, expiry date 12-MAY-2028) for prophylaxis. Previously administered products included Shingrix (received 1st dose on 27-JUN-2024) and Shingrix (received 2nd dose on 30-AUG-2024). On 13-APR-2026, the patient received the 3rd dose of Shingrix. On 13-APR-2026, an unknown time after receiving Shingrix, the patient experienced extra dose administered (Verbatim: 3rd dose administered). The outcome of the extra dose administered was not applicable. Additional Information: GSK Receipt Date: 30-APR-2026 The vaccine administration facility was the same as primary reporter.